Valuation: 4basebio PLC

Market Cap 76.45M 104M 89.4M 84.12M 144M 9.92B 146M 987M 387M 4.96B 389M 380M 16.52B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 76.75M 104M 89.75M 84.45M 144M 9.96B 146M 991M 388M 4.98B 390M 382M 16.59B EV / Sales 2026 *
27.4x
EV / Sales 2027 * 8.51x
Free-Float
38.75%
Yield 2026 *
-
Yield 2027 * -
1 week-6.29%
Current month-6.29%
1 month-6.29%
3 months+13.10%
6 months-11.35%
Current year-20.00%
1 week 484.16
Extreme 484.16
550
1 month 484.16
Extreme 484.16
550
Current year 420
Extreme 420
630
1 year 420
Extreme 420
930
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 2026-02-09
Chief Tech/Sci/R&D Officer - 2025-02-28
Chief Operating Officer - 2026-03-11
Director TitleAgeSince
Director/Board Member 48 2020-12-21
Director/Board Member 33 2024-08-07
Chairman 60 2025-07-07
Date Insider Type Main position Quantity % Market Cap.
2/16/26 Buy

Chief Executive Officer

2,650 0.0171%
2/11/26 Buy

Director

3,000 0.0193%
2/11/26 Buy

Director

1,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.29%-45.33%-20.00% 104M
-0.11%-2.38%+2.06%+19.57% 48.84B
+1.89%+5.08%+492.59%+629.24% 45.44B
+1.83%+2.75%+15.61%+91.22% 41.22B
-0.50%-1.56%+24.67%+12.17% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+0.59%-2.25% - - 16.25B
-1.14%-2.51%+27.52%+136.42% 16.67B
-0.49%-0.54%+2.96%+27.12% 14.08B
-2.60%-1.00%+77.85%+40.37% 13.68B
Average -0.33%-1.33%+68.36%+110.25% 26.86B
Weighted average by Cap. -0.02%-0.84%+103.95%+153.86%

Financials

2026 *2027 *
Net sales 2.8M 3.79M 3.27M 3.08M 5.27M 363M 5.34M 36.14M 14.16M 182M 14.23M 13.92M 605M 12M 16.25M 14.03M 13.2M 22.57M 1.56B 22.9M 155M 60.7M 779M 61M 59.68M 2.59B
Net income -17.1M -23.15M -20M -18.81M -32.16M -2.22B -32.63M -221M -86.49M -1.11B -86.93M -85.04M -3.7B -
Net Debt 300K 406K 351K 330K 564K 38.92M 573K 3.87M 1.52M 19.46M 1.53M 1.49M 64.83M 25.7M 34.8M 30.05M 28.28M 48.34M 3.33B 49.05M 332M 130M 1.67B 131M 128M 5.55B
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
26-08-18 GBX 492.00 0.00% 1,359
26-08-17 GBX 492.00 -10.55% 2,655
26-08-14 GBX 550.00 +4.76% 99
26-08-13 GBX 525.00 -4.55% 1,720
26-08-12 GBX 550.00 +4.76% 575
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.920GBP
Average target price
16.00GBP
Spread / Average Target
+225.20%

Annual profits - Rate of surprise